JN Biosciences LLC

The antigen-specific immune response is a complex biological process that is negatively regulated by checkpoint molecules, such as PD-1, CTLA-4, TIM-3, LAG-3 and TIGIT, and positively regulated by costimulatory molecules, such as OX40, GITR, HVEM, 4-1BB and CD40 that belong to the TNF receptor super-family.  Blocking the function of PD-1 or CTLA-4 by an antagonistic monoclonal IgG antibody has been shown to be effective for immunotherapy of cancer in humans.

JN Biosciences has generated antagonist antibodies against a variety of checkpoint molecules including, but not limited to, PD-1, PD-L1 and TIGIT (click here for an example).  These antibodies have been selected not only for their potent antagonist activity, but also for their superior developmentability, such as high expression, good stability and low immunogenicity potential.  One of JN Biosciences' anti-checkpoint antibodies has already been out-licenced and is investigated in clinical studies.